Table 3 Mean individual change of three anthropometric measures, from start to end of treatment (exit or 6 months), comparing 20 mg group to the placebo group (reference).

From: Side effects of low-dose tamoxifen: results from a six-armed randomised controlled trial in healthy women

 

All (N = 401)

Premenopausal (n = 149)

Postmenopausal (n = 252)

Interaction menopausal status

Anthropometrics

Mean change

20 to 0 mg (ref.)a

95%

confidence interval

Mean change

20 to 0 mg (ref.)a

95% confidence interval

Mean change

20 to 0 mg (ref.)a

95% confidence interval

P valueb

BMI (kg/m2)

−0.22

[−0.37, −0.06]

−0.28

[−0.56, −0.01]

−0.17

[−0.35, 0.02]

0.505

Weight (kg)

−0.59

[−1.01, −0.16]

−0.80

[−1.55, −0.05]

−0.43

[−0.92, 0.07]

0.417

Waist circumference (cm)

−0.74

[−2.57, 1.08]

−3.53

[−6.73, −0.32]

0.94

[−1.24, 3.12]

0.024

  1. BMI body mass index.
  2. aDifference in mean change comparing 20 to 0 mg (ref.) tamoxifen at end of treatment (at 6 months or date of discontinuation).
  3. bP values for interaction of menopausal status on the effect of tamoxifen.
  4. Significant values are in bold (P < 0.05).
Back to article page